ABOUT GUANINE

Building the Future of Programmable Biological Measurement

Guanine is developing a programmable biological measurement architecture designed to expand how biological information can be generated, interpreted, and deployed across healthcare systems.

The company emerged from the convergence of nanotechnology, semiconductor-style signal engineering, biological measurement, and systems architecture — with the goal of creating scalable biological testing systems capable of operating beyond the limitations of conventional diagnostic platforms.

Today, Guanine is developing a software-defined electrochemical sensing architecture capable of integrating signal generation, amplification, stabilization, multiplex encoding, and computational interpretation within a unified scalable platform.

HISTORY OF THE DNA SENSOR

Rapid Detection of Nucleic Acids

For decades, researchers sought to combine biology and semiconductor-style electronics to create rapid, low-cost systems capable of electronically measuring biological information.

Early pioneers demonstrated that biological molecules could directly interact with engineered nanoscale materials and generate measurable electrochemical signals.

At NASA Ames Research Center, researchers explored carbon nanotube biosensors designed to increase electron transfer efficiency and amplify biological signal generation. This work later contributed to the NASA spin-out Early Warning Inc., led by Guanine founder Neil Gordon.

These early nanosensor systems established important scientific foundations:

direct electrochemical biological sensing
nanoscale signal amplification
biological-electronic interfaces

However, most first-generation nanosensor architectures encountered critical limitations that prevented large-scale clinical deployment:

inadequate low-concentration sensitivity
instability and poor reproducibility
multiplex complexity
biological interference
high manufacturing cost

The promise of biology interacting with semiconductors

A NEW MEASUREMENT ARCHITECTURE

Six Generations of Technology

Following Early Warning, Guanine pursued a different approach to biological sensing.

Rather than relying on direct nucleotide oxidation alone, the architecture evolved toward synthetic electrochemical signal structures capable of amplification, stabilization, reversibility, and scalable multiplex encoding.

Across six technology generations, the platform progressively evolved toward a programmable biological measurement architecture integrating signal generation, amplification, stabilization, multiplex encoding, and computational biological interpretation within a unified scalable system.

CLINICAL VALIDATION AND TRANSLATION

Clinical Incubation at Mount Sinai's Elementa Labs

A major inflection point in Guanine’s evolution occurred through entry into Mount Sinai Health System’s Elementa Labs in New York City.

This collaboration enabled direct engagement with physicians, infectious disease specialists, microbiologists, emergency medicine teams, critical care experts, and hospital innovation leaders.

Clinical feedback consistently highlighted the need for biological decisions within the treatment window, broader pathogen coverage, faster susceptibility information, reduced laboratory dependence, and deployable testing architectures beyond centralized labs.

This milestone helped transition Guanine from a deep-technology platform effort toward a clinically aligned infrastructure company focused on scalable biological measurement.

Leadership

President and Founder

Neil Gordon

President, Founder, Inventor

B.Eng., MBA

Neil Gordon is the Founder of Guanine and inventor of Guanine’s software-defined electrochemical sensing architecture.

Neil was among the early business consultants working in nanotechnology commercialization, including engagements related to how nanoscale systems and semiconductor concepts could interact with biological measurement technologies.

He later led commercialization initiatives within the NASA-led CANEUS organization focused on advanced aerospace and micro-nano technologies, before spearheading the NASA spin-out Early Warning Inc., which pursued carbon nanotube biosensors for rapid pathogen detection.

These experiences helped shape the foundational concepts that ultimately evolved into Guanine’s multi-generation programmable biological measurement architecture.

Medical Advisor

Raj Bawa

Medical Advisor

MD, PhD

Dr. Bawa served the company with exceptional distinction across senior leadership roles, most notably as Vice President and Patent Law Counsel. In 2026, he assumed an advisory role, serving as Medical Advisor.

Trained as a microbiologist, biochemist, and physician, Dr. Bawa is a pioneer in clinical nanomedicine and recipient of the Lifetime Achievement Award from the American Society of Nanomedicine. He has authored more than 100 publications, edited 10 books, served as Primary Examiner at the U.S. Patent and Trademark Office for six years, is a Registered Patent Agent, and has worked at global pharmaceutical companies.

Dr. Bawa was a key contributor to Guanine’s scientific, regulatory, and intellectual property strategy. He provided critical leadership in protecting and advancing the company’s core innovations, significantly strengthening its intellectual property portfolio and long-term competitive position, thereby acting as the crucial link between scientific research, clinical practice, and commercial strategy.

LOOKING FORWARD

Enabling the Next Generation of Biological Measurement

Guanine’s initial deployment pathway begins with sepsis and rapid biological decision-making.

The broader opportunity extends beyond any individual disease category.

As healthcare becomes increasingly data-driven, scalable biological measurement may become foundational infrastructure for distributed healthcare, healthcare AI, pathogen surveillance, longitudinal monitoring, and future biological information systems.

Guanine is being designed to support this transition through programmable, scalable, lower-cost biological measurement architectures capable of expanding across multiple healthcare and OEM markets.